AKT is a therapeutic target in myeloproliferative neoplasms

The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN an...

詳細記述

保存先:
書誌詳細
主要な著者: Khan, Irum, Huang, Zan, Wen, Qiang, Stankiewicz, Monika J., Gilles, Laure, Goldenson, Benjamin, Schultz, Rachael, Diebold, Lauren, Gurbuxani, Sandeep, Finke, Christy M., Lasho, Terra L., Koppikar, Priya, Pardanani, Animesh, Stein, Brady, Altman, Jessica K., Levine, Ross L., Tefferi, Ayalew, Crispino, John D.
フォーマット: Artigo
言語:Inglês
出版事項: 2013
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023863/
https://ncbi.nlm.nih.gov/pubmed/23748344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.167
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料